Merck KGaA to acquire Silence Therapeutics in an all-cash deal
On October 19, Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, paying $20.00 per ADS in cash. The transaction is expected to close in the first quarter of 2027, subject to Silence shareholder approval, regulatory clearances and other customary conditions. Merck said the acquisition will expand its rare-disease capabilities through Silence’s Divesiran siRNA program for polycythemia vera.
Why it matters
The deal provides Silence holders with a cash exit at the agreed consideration, while Merck will add a Phase 2-supported, Phase 3-ready rare-disease program and fund the acquisition with new debt. Completion remains conditional on shareholder and regulatory approvals, so the transaction is not yet final.
Key facts
- 1Merck KGaA will pay $20.00 in cash for each Silence Therapeutics ADS. investing.com
- 2The transaction carries an equity value of $1.3 billion. investing.com
- 3The acquisition is expected to close in the first quarter of 2027, subject to approvals. finance.yahoo.com
- 4Securityholders representing approximately 14% of Silence Therapeutics' voting power agreed to support the transaction. finance.yahoo.com
- 5Divesiran produced an 88% responder rate versus 19% for placebo in the Phase 2 SANRECO study. finance.yahoo.com
- 6Merck plans to fund the acquisition with proceeds from new debt. finance.yahoo.com
Open questions
- Material 1 reports approximately $1.85 billion and $61 per share, while other materials report $1.3 billion of equity value and $20.00 per ADS; the materials do not reconcile these figures.
- Material 8 says completion is expected in the first half of 2027, while materials 2, 3 and 5 give the first quarter of 2027.
Summary written by AlphAI AI Desk from 20 of 37 sources. Not investment advice. Figures are as stated by the linked sources.